A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity

BACKGROUND: Maraviroc (MVC) is an allosteric CCR5 inhibitor used against HIV-1 infection. While MVC-resistant viruses have been identified in patients, it still remains incompletely known how they adjust their CD4 and CCR5 binding properties to resist MVC inhibition while preserving their replicativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Perez, Javier, Staropoli, Isabelle, Azoulay, Stéphane, Heinrich, Jean-Thomas, Cascajero, Almudena, Colin, Philippe, Lortat-Jacob, Hugues, Arenzana-Seisdedos, Fernando, Alcami, Jose, Kellenberger, Esther, Lagane, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470041/
https://www.ncbi.nlm.nih.gov/pubmed/26081316
http://dx.doi.org/10.1186/s12977-015-0177-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470041/
https://www.ncbi.nlm.nih.gov/pubmed/26081316
http://dx.doi.org/10.1186/s12977-015-0177-1

Ejemplares similares